Please use this identifier to cite or link to this item:
|Scopus||Web of Science®||Altmetric|
|Title:||Critical limb ischemia: current and novel therapeutic strategies|
|Citation:||Journal of Cellular Physiology, 2019; 234(9):14445-14459|
|Mohammadhossein Hassanshahi, Samira Khabbazi, Yaser Peymanfar, Alireza Hassanshahi, Zahra Hosseini‐Khah, Yu‐Wen Su, Cory J. Xian|
|Abstract:||Critical limb ischemia (CLI) is the advanced stage of peripheral artery disease spectrum and is defined by limb pain or impending limb loss because of compromised blood flow to the affected extremity. Current conventional therapies for CLI include amputation, bypass surgery, endovascular therapy, and pharmacological approaches. Although these conventional therapeutic strategies still remain as the mainstay of treatments for CLI, novel and promising therapeutic approaches such as proangiogenic gene/protein therapies and stem cell-based therapies have emerged to overcome, at least partially, the limitations and disadvantages of current conventional therapeutic approaches. Such novel CLI treatment options may become even more effective when other complementary approaches such as utilizing proper bioscaffolds are used to increase the survival and engraftment of delivered genes and stem cells. Therefore, herein, we address the benefits and disadvantages of current therapeutic strategies for CLI treatment and summarize the novel and promising therapeutic approaches for CLI treatment. Our analyses also suggest that these novel CLI therapeutic strategies show considerable advantages to be used when current conventional methods have failed for CLI treatment.|
|Keywords:||angiogenesis; bio-scaffolds; critical limb ischemia; stem cell therapy|
|Rights:||© 2019 Wiley Periodicals, Inc.|
|Appears in Collections:||Biochemistry publications|
Files in This Item:
There are no files associated with this item.
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.